

Chapter 23

REFERENCES

1. Chopra M, Galbraith S, Damton-Hill I. A global response to a global problem: the epidemic of overnutrition. *Bull World Health Organ.* 2002;80:952.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. *JAMA.* 2002;288:1723.
3. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the incidence report. *Obes Surg.* 1998;6:51S.
4. Ho SY, Lam TH, Janus ED, et al. Waist to stature ratio is more strongly associated with cardiovascular risk factors than other indices. *Ann Epidemiol.* 2003;13:683.
5. Lemmens HJ, Brodsky JB: Anesthetic drugs and bariatric surgery. *Expert Rev Neurother.* 2006;6:1107.
6. Pai MP, Paloucek FP: The origin of the “ideal” body weight equations. *Ann Pharmacother.* 2000;34:1066.
7. Lemmens HJ, Brodsky JB, Bernstein DP. Estimating ideal body weight—a new formula. *Obes Surg.* 2005;15:1082.
8. Jubber AS. Respiratory complications of obesity. *Int J Clin Pract.* 2004;58:573.
9. Chen Y, Horne SL, Dosman JA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. *Thorax.* 1993;48:375
10. Kress JP, Pohlman AS, Alverdy J, et al. The impact of morbid obesity on oxygen cost of breathing (VO₂ RESP) at rest. *Am J Respir Crit Care Med.* 1999;160:883
11. Biring MS, Lewis MI, Liu JT, et al. Pulmonary physiologic changes of morbid obesity. *Am J Med Sci.* 1999;318:293.
12. Flemons WW. Obstructive sleep apnea. *N Engl J Med.* 2002;347:498.
13. Benumof JL. Obesity, sleep apnea, the airway and anesthesia. *Curr Opin Anaesthesiol.* 2004;17:21.
14. Olson AL, Zwillich C. The obesity hypoventilation syndrome. *Am J Med.* 2005;118:948.
15. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology.* 2008;108:812.
16. Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, impact, and outcome. *Am J Med.* 2004;116:1.
17. Burwell CS, Robin ED, Whaley RD, et al. External obesity is associated with alveolar hypoventilation—a Pickwickian syndrome. *Am J Med.* 1956;25:815.
18. Blankfield RP, Hudgel DW, Tapolyai AA, et al. Bilateral leg edema, obesity, pulmonary hypertension, and obstructive sleep apnea. *Arch Int Med.* 2000;160:2357.
19. Akashiba T, Kawahara S, Kosaka N, et al. Determinants of chronic hypercapnia in Japanese men with obstructive sleep apnea syndrome. *Chest.* 2002;121:415.
20. Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. *Chest.* 2001;120:369.
21. Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. *Endocrinol Metab Clin North Am.* 2003;32:855.
22. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. *Br J Anaesth.* 2000;85:91.
23. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. *N Engl J Med.* 1990;322:882.
24. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. *N Engl J Med.* 2002;347:305.
25. Fraley MA, Bircham JA, Senkottaiyan N, et al. Obesity and the electrocardiogram. *Obes Rev.* 2005;6:275.
26. van Baak MA. The peripheral sympathetic nervous system in human obesity. *Obes Rev.* 2001;2:3.
27. Thomas F, Bean K, Pannier B, et al. Cardiovascular mortality in overweight subjects. The key role of associated risk factors. *Hypertension.* 2005;46:654.
28. Wolf C, Tanner M. Obesity. *West Med J.* 2002;176:23.
29. Bray GA. Medical consequences of obesity. *J Clin Endocrinol Metab.* 2004;89:2583.
30. Faber DR, de Groot PG, Visseren FLJ. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. *Obes Rev.* 2009;10:554.
31. Xing J, Chen JD. Alterations in gastrointestinal motility in obesity. *Obes Res.* 2004;12:1723.
32. Harter RL, Kelly WB, Kramer MG, et al. A comparison of the volume and pH of gastric contents of obese and lean surgical patients. *Anesth Analg.* 1998;86:147.
33. Maltby JR, Pytka S, Watson NC, et al. Drinking 300 ml of clear fluid two hours before surgery has no effect on gastric fluid volume and pH in fasting and non-fasting obese patients. *Can J Anesth.* 2004;51:111.
34. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA.* 2003;290:66.

35. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. *Clin Pharmacokinet.* 2000; 39:215.
36. Cotler SJ, Vitello JM, Guzman G, et al. Hepatic decompensation after gastric bypass surgery for morbid obesity. *Dig Dis Sci.* 2004;49:1563.
37. Matteoni C, Younossi ZM, McCullough A. Non alcoholic fatty liver disease: a spectrum of clinical pathological severity. *Gastroenterology.* 1999;116:1413.
38. Shalhub S, Parsee A, Gallagher SF, et al. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. *Obes Surg.* 2004;14:54.
39. Dittrick GW, Thompson JS, Campos D, et al. Gallbladder pathology in morbid obesity. *Obes Surg.* 2005;15:238.
40. Rosenberg DE, Jabbour SA, Goldstein BJ. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. *Diabetes Obes Metab.* 2005;7:642.
41. Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. *Obes Surg.* 2005;15:474.
42. Moulin de Moraes CM, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. *Obes Surg.* 2005;15:1287.
43. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. *Arch Dis Child.* 2002;87:320.
44. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. *Endocrinol Metab Clin North Am.* 2002;31:173.
45. Raftopoulos Y, Gagné DJ, Pappasavvas P, et al. Improvement in hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. *Obes Surg.* 2004;14:509.
46. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. *J Am Soc Nephrol.* 2003;14:1480.
47. Zimmet PZ, Alberti KG, Shaw E. Mainstreaming the metabolic syndrome: a definitive diagnosis. *Med J Aust.* 2005; 183:175.
48. Casati A, Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. *J Clin Anesth.* 2005;17:134.
49. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. *J Pharm Sci.* 1999;88:1.
50. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. *J Am Soc Nephrol.* 2001;12:1211.
51. Wada DR, Björkman S, Ebling WF, et al. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. *Anesthesiology.* 1997;87:884.
52. Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. *Anesthesiology.* 1993;78:657.
53. Whitwam JG. Flumazenil and midazolam in anaesthesia. *Acta Anaesthesiol Scand.* 1995;108:S15.
54. Pühringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese patients. *Eur J Anaesthesiol.* 1999; 16:507.
55. Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. *Anesth Analg.* 2000;90:576.
56. Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamics effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. *Anesth Analg.* 2004;99:1086.
57. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. *Anesth Analg.* 1992;74:515.
58. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, et al. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. *Anesth Analg.* 1996;83:1076.
59. Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. *Anesth Analg.* 2004;99:1090.
60. Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight, and obese female patients. *Br J Anaesth.* 2006;97:160.
61. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. *Anesth Analg.* 2007;104:569.
62. Shibutani K, Inchiosa Jr. MA, Sawada K, et al. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass"). *Anesthesiology.* 2004;101:603.
63. Shibutani K, Inchiosa Jr. MA, Sawada K, et al. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. *Br J Anaesth.* 2005;95:377.
64. Slepchenko G, Simon N, Goubaux B, et al. Performance of target-controlled sufentanil infusion in obese patients. *Anesthesiology.* 2003;98:65.
65. Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese vs lean patients. *Anesthesiology.* 1998;89:562.
66. Hofer RE, Sprung J, Sarr MG, et al. Anesthesia for a patient with morbid obesity using dexmedetomidine without narcotics. *Can J Anesth.* 2005;52:176.
67. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. *Int Obes Relat Metab Disord.* 2003;27:591.
68. McWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. *Ann Pharmacother.* 2003;37:510.
69. Patel PN, Pathak R. Rimobant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity. *Am J Health Syst Pharm.* 2007;64:481.
70. Rubino F, Gagner M, Gentileschi P, et al. The early effect of Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. *Ann Surg.* 2004;240:236.
71. Mognol P, Vignes S, Chosidow D, et al. Rhabdomyolysis after laparoscopic bariatric surgery. *Obes Surg.* 2004;14:19.
72. Wool DB, Lemmens HJM, Brodsky JB, et al. Intraoperative fluid replacement and postoperative creatine phosphokinase levels in laparoscopic bariatric patients. *Obes Surg.* 2010;20:698.
73. Elliot C, Kiely DG. Pulmonary hypertension: diagnosis and treatment. *Clin Med.* 2004;4:211.
74. Catheline JM, Bihan H, Quang TL, et al. Preoperative cardiac and pulmonary assessment in bariatric surgery. *Obes Surg.* 2008;18:271.
75. Chang C, Adams-Huet B, Provost DA. Acute post-gastric reduction surgery (APGARS) neuropathy. *Obes Surg.* 2004;14:182.
76. Ogunnaike BO, Jones SB, Jones DB, et al. Anesthetic considerations for bariatric surgery. *Anesth Analg.* 2002;95:1793.

77. Kabon B, Nagele A, Reddy D, et al. Obesity decreases perioperative tissue oxygenation. *Anesthesiology*. 2004;100:274.
78. Edmonds MJ, Crichton TJ, Runciman WB, et al. Evidence-based risk factors for postoperative deep vein thrombosis. *ANZ J Surg*. 2004;74:1082.
79. Mantilla CB, Horlocker TT, Schroeder DR, et al. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. *Anesthesiology*. 2003;99:552.
80. Gonzalez QH, Tisher DS, Plata-Munoz JJ, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. *Surg Endosc*. 2004;18:1082.
81. Keeling WB, Haines K, Stone PA, et al. Current indications for inferior vena cava filter insertion in patients undergoing surgery for morbid obesity. *Obes Surg*. 2005;15:1009.
82. Sapala JA, Wood MH, Schuhknecht MP, et al. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. *Obes Surg*. 2003;13:819.
83. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. *Obes Surg*. 2000;10:7.
84. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. *Obes Surg*. 2003;13:249.
85. Siyam MA, Benhamou D. Difficult endotracheal intubation in patients with sleep apnea syndrome. *Anesth Analg*. 2002;95:1098.
86. Ezri T, Medalion B, Weisenberg M, et al. Increased body mass per se is not a predictor of difficult laryngoscopy. *Can J Anesth*. 2003;50:179.
87. Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. *Anesth Analg*. 2002;94:732.
88. Commission on the Provision of Surgical Services. *Guidelines for Day Case Surgery. A Report of the Royal College of Surgeons of England*. Rev. ed. London, UK: Royal College of Surgeons of England; 1992.
89. Atkins M, White J, Ahmed K. Day surgery and body mass index: results of a national survey. *Anaesthesia*. 2002;57:169.
90. Bryson GL, Chung F, Cox RG, et al. Patient selection in ambulatory anesthesia—an evidence-based review: part II. *Can J Anesth*. 2004;51:782.
91. Friedman Z, Chung F, Wong DT. Ambulatory surgery adult patient selection criteria—a survey of Canadian anesthesiologists. *Can J Anesth*. 2004;51:437.
92. Servin F. Ambulatory anesthesia for the obese patient. *Curr Opin Anaesthesiol*. 2006;19:597.
93. Chung F, Mezei G, Tong D. Pre-existing medical conditions as predictors of adverse events in day-case surgery. *Br J Anaesth*. 1999;83:262.
94. Davies KE, Houghton K, Montgomery JE. Obesity and day-case surgery. *Anaesthesia*. 2001;56:1112.
95. Nielsen KC, Guller U, Steele SM, et al. Influence of obesity on surgical regional anesthesia in the ambulatory setting: an analysis of 9038 blocks. *Anesthesiology*. 2005;102:181.
96. Warner MA, Warner ME, Martin JT. Ulnar neuropathy: incidence, outcome and risk factors in sedated anesthetized patients. *Anesthesiology*. 1994;81:1332.
97. Thaisetthawatkul P, Collazo-Clavell ML, Sarr MG, et al. A controlled study of peripheral neuropathy after bariatric surgery. *Neurology*. 2004;63:1462.
98. Koffman BM, Greenfield LJ, Ali II, Pirzada NA. Neurologic complications after surgery for obesity. *Muscle Nerve*. 2006;33:166.
99. Perilli V, Sollazzi L, Modesti C, et al. Comparison of positive end-expiratory pressure with reverse Trendelenburg position in morbidly obese patients. *Obes Surg*. 2003;13:605.
100. Brodsky JB. Positioning the morbidly obese patient for anesthesia. *Obes Surg*. 2002;12:751.
101. Hamza J, Smida M, Benhamou D, et al. Parturient's posture during epidural puncture affects the distance from skin to epidural space. *J Clin Anesth*. 1995;7:1.
102. Pierin AM, Alavarce DC, Gusmao JL, et al. Blood pressure measurement in obese patients: comparison between upper arm and forearm measurements. *Blood Press Monit*. 2004;9:101.
103. Juvin P, Blarel A, Bruno F, et al. Is peripheral line placement more difficult in obese than in lean patients? *Anesth Analg*. 2003;96:1218.
104. Coussa M, Proietti S, Schnyder P, et al. Prevention of atelectasis formation during the induction of general anesthesia in morbidly obese patients. *Anesth Analg*. 2004;98:1491.
105. Goldberg ME, Norris MC, Larijani GE, et al. Preoxygenation in the morbidly obese: a comparison of two techniques. *Anesth Analg*. 1989;68:520.
106. Altermatt FR, Muñoz HR, Delfino AE, et al. Pre-oxygenation in the obese patient: effects of position on tolerance to apnoea. *Br J Anaesth*. 2005;95:706.
107. Dixon BJ, Dixon JB, Carden JR, et al. Preoxygenation is more effective in the 25° head-up position than in the supine position in severely obese patients. *Anesthesiology*. 2005;102:1110.
108. Boyce JR, Ness T, Castroman P. A preliminary study of the optimal positioning for the morbidly obese patient. *Obes Surg*. 2003;13:4.
109. Brodsky JB, Foster PE. Succinylcholine and morbid obesity. *Obes Surg*. 2003;13:138.
110. Levitan RM, Mechem CC, Ochroch EA, et al. Head-elevated laryngoscopy position: improving laryngeal exposure during laryngoscopy by increasing head elevation. *Ann Emerg Med*. 2003;41:322.
111. Collins JS, Lemmens HJ, Brodsky JB, et al. Laryngoscopy and morbid obesity: a comparison of the “sniff” and “ramped” positions. *Obes Surg*. 2004;14:1171.
112. Rich JM. Use of an elevation pillow to produce the head-elevated laryngoscopy position for airway management in morbidly obese and large-framed patients. *Anesth Analg*. 2004;98:264.
113. Nissen MD, Graves JM. An inflatable, multichambered upper body support for the placement of the obese patient in the head-elevated laryngoscopy position (letter). *Anesth Analg*. 2007;104:1305.
114. De Baerdemaeker LE, Struys MM, Jacobs S, et al. Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane. *Br J Anaesth*. 2003;91:638.
115. Torri G, Casati A, Albertin A, et al. Randomized comparison of isoflurane and sevoflurane for laparoscopic banding in morbidly obese patients. *J Clin Anesth*. 2001;13:565.
116. Arain SR, Barth CD, Shankar H, et al. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. *J Clin Anesth*. 2005;17:413.
117. Strum EM, Szenohradszki J, Kaufman WA, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. *Anesth Analg*. 2004;99:1848.

118. La Colla L, Albertin A, La Colla G, et al. Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. *Br J Anaesth*. 2007;99:353.
119. McKay RE, Malhotra A, Cakmakkaya OS, et al. Effect of increased body mass index and anesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. *Br J Anaesth*. 2010;104:175.
120. Pandazi A, Bourlioti A, Kostopanagiotou G. Bispectral index (BIS) monitoring in morbidly obese patients undergoing gastric bypass surgery: experience in 23 patients. *Obes Surg*. 2005;15:58.
121. Frink EJ, Malan TP, Brown EA, et al. Plasma inorganic fluoride levels with sevoflurane anesthesia in morbidly obese and non-obese patients. *Anesth Analg*. 1993;76:1333.
122. Song D, Whitten CW, White PF. Remifentanyl infusion facilitates early recovery for obese outpatients undergoing laparoscopic cholecystectomy. *Anesth Analg*. 2000;90:1111.
123. Hofer RE, Sprung J, Sarr MG, et al. Anesthesia for a patient with morbid obesity using dexmedetomidine without narcotics. *Can J Anesth*. 2005;52:176.
124. Bardoczky GI, Yernault JC, Houben JJ, et al. Large tidal volume ventilation does not improve oxygenation in morbidly obese patients during anesthesia. *Anesth Analg*. 1995;81:385.
125. Sprung J, Whalley DG, Falcone T, et al. The effects of tidal volume and respiratory rate on oxygenation and respiratory mechanics during laparoscopy in morbidly obese patients. *Anesth Analg*. 2003;97:268.
126. Talab HF, Zabani IA, Abdelrahman HS, et al. Intraoperative ventilator strategies for prevention of pulmonary atelectasis in obese patients undergoing laparoscopic bariatric surgery. *Anesth Analg*. 2009;109:1511.
127. Grau T, Leipold RW, Fatehi S, et al. Real time ultrasonic observation of combined spinal-epidural anaesthesia. *Eur J Anaesthesiol*. 2004;21:25.
128. Eidelman A, Shulman MS, Novak GM. Fluoroscopic imaging for technically difficult spinal anesthesia. *J Clin Anesth*. 2005;17:69.
129. Johnson TW, Morgan R, Smalley P. Radiographic guided epidural placement. *Anaesthesia*. 2003;58:485.
130. Tsui BC, Gupta S, Finucane B. Confirmation of epidural catheter placement using nerve stimulation. *Can J Anesth*. 1998;45:640.
131. Michaloudis D, Fraidakis O, Petrou A, et al. Continuous spinal anesthesia/analgesia for perioperative management of morbidly obese patients undergoing laparotomy for gastroplastic surgery. *Obes Surg*. 2000;10:220.
132. Ogunnaike BO, Whitten CW. Bariatric surgery and the prevention of postoperative respiratory complications (In reply). *Anesth Analg*. 2004;98:1809.
133. Eichenberger A, Proietti S, Wicky S, et al. Morbid obesity and postoperative pulmonary atelectasis: an underestimated problem. *Anesth Analg*. 2002;95:1788.
134. Huerta S, DeShields S, Shpiner R, et al. Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-y gastric bypass. *J Gastrointest Surg*. 2002;6:354.
135. Charghi R, Backman S, Christou N, et al. Patient controlled IV analgesia is an acceptable pain management strategy in morbidly obese patients undergoing gastric bypass surgery. A retrospective comparison with epidural analgesia. *Can J Anesth*. 2003;50:672.
136. Schumann R, Shikora S, Weiss JM, et al. A comparison of multimodal perioperative analgesia to epidural pain management after gastric bypass surgery. *Anesth Analg*. 2003;96:469.
137. Schumann R, Jones SB, Cooper B, et al. Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007. *Obesity*. 2009;17:889.
138. Feld JM, Laurito CE, Beckerman M, et al. Non-opioid analgesia improves pain relief and decreases sedation after gastric bypass surgery. *Can J Anesth*. 2003;50:336.
139. DeSilva RA, Lown B. Energy requirement for defibrillation of a markedly overweight patient. *Circulation*. 1978;57:827.
140. Brunette DD. Resuscitation of the obese patient. *Am J Emerg Med*. 2004;22:40.